Search Results
Site Search
Getting Organized in the New Year: Tips for Managing Email - Insights
This month's microlearning focuses on email management. When you manage your time well, you can prioritize the most important emails, handle urgent tasks quickly, and avoid the stress of an overflowing inbox. Without a plan, it’s easy to...
Cytology Specimen Utilization: A Proven Approach to Genetic Sequencing - Insights
PACE/State of FL - The role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients with cancer.
4 statistics that showcase the broad impact of laboratory medicine - Insights
Medical Laboratory Professionals Week is a time to appreciate the profound impact of laboratory medicine on healthcare and innovation.
Integration, innovation, precision: Propelling leading-edge diagnostics - Insights
The third episode of “Life of a Specimen” video series discusses the integration that drives the development of innovative tests, including the movement disorders evaluation, at Mayo Clinic Laboratories.
Benefits of Automation in the Laboratory: Erin Graf, Ph.D. - Insights
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Erin Graf, Ph.D., co-director of Microbiology in the Department of Laboratory Medicine and...
Monitoring Tropical Storm Helene - Insights
Tropical Storm Helene is approaching the Florida Gulf Coast and is expected to become a hurricane. These weather conditions may impact areas in the United States, including Alabama, Florida, Georgia, and South Carolina. We continue to...
Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D. - Insights
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and...
New Tests Launched Archives - Insights
Skip to Content MayoACCESS MayoLINK...
Building Blocks for a Successful Contact Center - Insights
Skip to Content MayoACCESS MayoLINK Register My Dashboard...
Test panel guides diagnosis of early onset IBD: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy...
Paul Jannetto, Ph.D., explains the advantages that Mayo Clinic Laboratories' oral fluid drug screening offers over typical urine tests. Oral samples are easier to collect and harder to adulterate.
Assay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. - Insights
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal...
Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients'...
Assay enhances and simplifies M-proteins screening: David Murray, M.D., Ph.D. - Insights
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASSFIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the...
Testing Aids Nicotine-Use Cessation: Paul Jannetto, Ph.D. - Insights
Tobacco use is the leading cause of preventable death in the United States. In this test-specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' nicotine testing benefits patients...
Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D. - Insights
Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's...
Test helps identify elusive central nervous system pathogens: Robin Patel, M.D. - Insights
Robin Patel, M.D., explains how a new Mayo Clinic Laboratories' assay can identify central nervous system pathogens that standard tests fail to detect. Rapid, precise diagnosis is essential to preventing long-term effects from these...
Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D. - Insights
Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating...
Antibody against the GABA-A receptor is a biomarker of autoimmune encephalopathy that occurs across the lifespan, and disproportionately affects children. In this test-specific episode of the "Answers From the Lab" podcast, Andrew McKeon,...
Linnea Baudhuin, Ph.D., and Kate Kotzer, M.S., CGC, describe how Mayo Clinic Laboratories' postmortem genetic tests can provide answers after a sudden unexplained cardiac death. Test results are important for managing family members' risk...
Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for...
Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in...
Tests aid diagnosis of primary biliary cholangitis: Anne Tebo, Ph.D. - Insights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune...
Updated assay guides diagnosis of autoimmune liver disease: Anne Tebo, Ph.D. - Insights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.
Lipid assay improves cardiovascular risk prediction: Jeff Meeusen, Ph.D. - Insights
Jeff Meeusen, Ph.D., explains how Mayo Clinic Laboratories' new MI-Heart Ceramides assay helps guide the management of patients with mildly to moderately high cholesterol. The test measures levels of lipids beyond cholesterol that boost...
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating...
Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel is the most comprehensive test available for inherited Parkinson's disease. The new panel covers all mutations known to cause the...
Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D. - Insights
Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal...
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay...
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' gynecological NGS panels provide focused assessments of gynecological cancers. The cost-effective tests fill the gap between single gene assays and large cancer panels,...
Urologic panels provide focused cancer testing: Sounak Gupta, M.B.B.S., Ph.D. - Insights
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS...
Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing...
New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. - Insights
Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test...
Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D. - Insights
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely...
Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of...
Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test...
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' enhanced MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted...
Assay identifies rare tick-borne bacteria: Bobbi Pritt, M.D. - Insights
Bobbi Pritt, M.D., explains how Mayo Clinic Laboratories' new assay identifies less-common tick-borne bacteria in whole blood. The assay is recommended when tick-borne bacterial infection is suspected but standard testing is unrevealing.
Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing...
Assay Aids Diagnosis of Resistant Hypertension: John Lieske, M.D., and Sandra Taler, M.D. - Insights
John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test can detect antihypertensive medications in urine, providing evidence of...
Hypermethylation Test Guides Lynch Syndrome Care: Megan Hoenig, M.S., M.P.H., CGC - Insights
Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases the risk for many...
Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D. - Insights
John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.
Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related...
Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild...
An efficient, cost-effective, fungal testing alternative: Elitza Theel, Ph.D. - Insights
Elitza Theel, Ph.D., explains how Mayo Clinic Laboratories' unique Histoplasma/Blastomyces test provides cost-effective evaluation for fungal infections that cause pulmonary illness. The assay reliably detects both Histoplasma and...
Chromosomal microarray better informs brain tumor diagnosis - Insights
Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor...
Accurately characterize marijuana use through urine THC testing - Insights
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories’ new marijuana monitoring evaluation, which identifies metabolites of both delta-9 tetrahydrocannabinol (THC) and delta-8 THC to accurately identify and...
Results report simplifies urine test interpretation: John Lieske, M.D. - Insights
John Lieske, M.D., explains why it's now easier for clinicians to pull information from Mayo Clinic Laboratories' supersaturation test report. An updated format summarizes complex information to help guide the treatment of kidney stones.
Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide targeted cancer surveillance for...
Zhiyv (Neal) Niu, Ph.D., and Christopher Klein, M.D., explain how Mayo Clinic Laboratories' updated neuromuscular gene panel informs diagnosis and treatment. The phenotype-based panel covers the complete list of neuromuscular genes and...